Paul Consroe

3.4k total citations
59 papers, 2.6k citations indexed

About

Paul Consroe is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Paul Consroe has authored 59 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pharmacology, 38 papers in Cellular and Molecular Neuroscience and 7 papers in Molecular Biology. Recurrent topics in Paul Consroe's work include Cannabis and Cannabinoid Research (36 papers), Neuroscience and Neuropharmacology Research (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Paul Consroe is often cited by papers focused on Cannabis and Cannabinoid Research (36 papers), Neuroscience and Neuropharmacology Research (31 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). Paul Consroe collaborates with scholars based in United States, Israel and Brazil. Paul Consroe's co-authors include Henry I. Yamamura, William R. Roeske, Reuven Sandyk, Thomas H. Burkey, Stuart R. Snider, Karl H. Schram, Robert S Landsman, Raphael Mechoulam, Judith A. Rein and Roger G. Pertwee and has published in prestigious journals such as Science, JAMA and Gastroenterology.

In The Last Decade

Paul Consroe

59 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Consroe United States 27 2.0k 1.4k 445 316 287 59 2.6k
Eileen M. Briley United States 14 1.9k 0.9× 1.3k 0.9× 348 0.8× 224 0.7× 434 1.5× 15 2.6k
C.W. Gerth Germany 14 1.4k 0.7× 800 0.6× 308 0.7× 135 0.4× 435 1.5× 16 2.3k
Daniela Viganò Italy 32 2.3k 1.2× 2.1k 1.5× 505 1.1× 154 0.5× 329 1.1× 38 3.0k
Alexandra Šulcová Czechia 22 1.0k 0.5× 933 0.7× 280 0.6× 146 0.5× 326 1.1× 99 1.8k
Sandra P. Welch United States 34 2.4k 1.2× 2.2k 1.6× 454 1.0× 146 0.5× 940 3.3× 90 3.7k
A. Makriyannis United States 24 1.6k 0.8× 1.2k 0.8× 367 0.8× 119 0.4× 387 1.3× 52 2.2k
Francisco Navarrete Spain 28 1.3k 0.7× 1.0k 0.7× 357 0.8× 114 0.4× 289 1.0× 95 2.4k
Felice Nava Italy 26 1.2k 0.6× 742 0.5× 315 0.7× 106 0.3× 380 1.3× 65 2.5k
G. B. Chesher Australia 25 745 0.4× 679 0.5× 250 0.6× 86 0.3× 208 0.7× 78 1.6k
Joel E. Schlosburg United States 34 2.1k 1.0× 2.2k 1.5× 654 1.5× 148 0.5× 1.0k 3.6× 49 4.4k

Countries citing papers authored by Paul Consroe

Since Specialization
Citations

This map shows the geographic impact of Paul Consroe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Consroe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Consroe more than expected).

Fields of papers citing papers by Paul Consroe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Consroe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Consroe. The network helps show where Paul Consroe may publish in the future.

Co-authorship network of co-authors of Paul Consroe

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Consroe. A scholar is included among the top collaborators of Paul Consroe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Consroe. Paul Consroe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Consroe, Paul. (1998). Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders. Neurobiology of Disease. 5(6). 534–551. 105 indexed citations
2.
Burkey, Thomas H., Raymond M. Quock, Paul Consroe, William R. Roeske, & Henry I. Yamamura. (1997). Δ9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. European Journal of Pharmacology. 323(2-3). R3–R4. 58 indexed citations
3.
Hosohata, Yoshiaki, Raymond M. Quock, Keiko Hosohata, et al.. (1997). AM630 antagonism of cannabinoid-stimulated [35S]GTPγS binding in the mouse brain. European Journal of Pharmacology. 321(1). R1–R3. 55 indexed citations
4.
Herrier, Richard N., et al.. (1997). The Use of Student-Centered, Problem-Based, Clinical Case Discussions to Enhance Learning in Pharmacology and Medicinal Chemistry. American Journal of Pharmaceutical Education. 61(4). 441–446. 21 indexed citations
5.
Consroe, Paul, et al.. (1997). The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis. European Neurology. 38(1). 44–48. 250 indexed citations
6.
Knapp, Richard J., et al.. (1996). Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport. 7(2). 593–596. 33 indexed citations
7.
Musty, Richard E., Patricia H. Reggio, & Paul Consroe. (1995). A review of recent advances in cannabinoid research and the 1994 international symposium on cannabis and the cannabinoids. Life Sciences. 56(23-24). 1933–1940. 26 indexed citations
8.
Consroe, Paul, et al.. (1991). Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacology Biochemistry and Behavior. 40(3). 517–522. 69 indexed citations
9.
Consroe, Paul, James Allender, Stuart R. Snider, et al.. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology Biochemistry and Behavior. 40(3). 701–708. 253 indexed citations
10.
Mechoulam, Raphael, J. J. Feigenbaum, N. Lander, et al.. (1988). Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Cellular and Molecular Life Sciences. 44(9). 762–764. 156 indexed citations
11.
Sandyk, Reuven, Colin R. Bamford, Robert P. Iacono, Paul Consroe, & Mark A. Gillman. (1988). The Electromyographic Silent Period is Reduced in Individuals at Risk for Huntington's disease. International Journal of Neuroscience. 40(1-2). 109–110. 4 indexed citations
12.
Iacono, Robert P., et al.. (1988). Intraspinal Opiates for Treatment of Intractable Pain in the Terminally Ill Cancer Patient. International Journal of Neuroscience. 38(1-2). 111–119. 1 indexed citations
13.
Mechoulam, Raphael, N. Lander, Morris Srebnik, et al.. (1987). Stereochemical Requirements for Cannabimimetic Activity. PsycEXTRA Dataset. 79. 15–30. 27 indexed citations
14.
Consroe, Paul & Raphael Mechoulam. (1987). Anticonvulsant and Neurotoxic Effects of Tetrahydrocannabinol Stereoisomers. PsycEXTRA Dataset. 79. 59–66. 5 indexed citations
15.
Consroe, Paul, et al.. (1983). Convulsant-anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits. Behavior Genetics. 13(2). 205–211. 6 indexed citations
16.
Consroe, Paul, et al.. (1981). Rabbit behavioral model of marijuana psychoactivity in humans. Medical Hypotheses. 7(8). 1079–1090. 10 indexed citations
17.
Consroe, Paul, Albert L. Picchioni, & Lincoln Chin. (1979). Audiogenic seizure susceptible rats.. PubMed. 38(10). 2411–6. 61 indexed citations
18.
Consroe, Paul, et al.. (1977). Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.. Journal of Pharmacology and Experimental Therapeutics. 201(1). 26–32. 110 indexed citations
19.
Jones, Byron, Paul Consroe, & Hugh E. Laird. (1976). The interaction of Δ9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm. European Journal of Pharmacology. 38(2). 253–259. 5 indexed citations
20.
Consroe, Paul, Byron Jones, & Lincoln Chin. (1975). Δ9-Tetrahydrocannabinol, EEG and behavior: The importance of adaptation to the testing milieu. Pharmacology Biochemistry and Behavior. 3(2). 173–177. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eileen M. Briley Breakdown of academic impact, for papers by C.W. Gerth Breakdown of academic impact, for papers by Daniela Viganò Breakdown of academic impact, for papers by Alexandra Šulcová Breakdown of academic impact, for papers by Sandra P. Welch Breakdown of academic impact, for papers by A. Makriyannis Breakdown of academic impact, for papers by Francisco Navarrete Breakdown of academic impact, for papers by Felice Nava Breakdown of academic impact, for papers by G. B. Chesher Breakdown of academic impact, for papers by Joel E. Schlosburg
Rankless by CCL
2026